Testing a second round of upadacitinib for ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests if a higher dose of upadacitinib can help people with ulcerative colitis who stopped responding to the 30 mg daily dose. It aims to see if re-inducing with a stronger dose can bring back symptom control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have moderate to severe ulcerative colitis that initially improved with upadacitinib but then stopped responding to the 30 mg daily dose within the last 8 weeks.
- You have active disease shown by a colonoscopy with a score of 2 or 3 on the endoscopy subscore.
- Your blood tests show your liver, kidneys, and blood cells are within safe ranges.
- You are not currently using strong medications that affect how upadacitinib is processed in the body without your doctor's knowledge.
- You do not have active infections, a history of certain cancers, or a past reaction to upadacitinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
This trial tests whether two medications, vedolizumab (a biologic given by IV) and upadacitinib (a pill), work together to help people with moderate to severe ulcerative colitis. The goal is to see if this combination is safe and effective for controlling symptoms and healing the colon.
This trial tests a medication called upadacitinib for people hospitalized with a severe ulcerative colitis flare. It could help control inflammation and reduce symptoms.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.